SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Genmab Commences New Arbitration Under License Agreement With Janssen

reuters.com · 06/09/2022 17:36
BRIEF-Genmab Commences New Arbitration Under License Agreement With Janssen

Genmab A/S GNMSF:

  • GENMAB COMMENCES NEW ARBITRATION UNDER LICENSE AGREEMENT WITH JANSSEN

  • GENMAB A/S - WHILE ARBITRATION IS PENDING, GENMAB'S VARIOUS COLLABORATIONS WITH JANSSEN WILL CONTINUE

  • GENMAB A/S - IN THIS NEW ARBITRATION, GENMAB IS CONSEQUENTLY SEEKING AN AWARD OF $405 MILLION PLUS INTEREST

  • GENMAB A/S - COMMENCED A NEW ARBITRATION UNDER ITS LICENSE AGREEMENT WITH JANSSEN BIOTECH, INC. (JANSSEN) FOR DARATUMUMAB

  • GENMAB - SEEKING AWARD FOR DARZALEX FASPRO IN NEW ARBITRATION WITH JANSSEN

  • GENMAB - SEEKING AWARD FOR DECLARATION THAT IT IS ENTITLED TO A NEW 13-YEAR ROYALTY TERM FROM DATE OF DARZALEX FASPRO'S FIRST COMMERCIAL SALE

Source text for Eikon: ID:nGNXbPxns8

Further company coverage: GNMSF